AlloVir is the global leader in developing VST immunotherapies. We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases. AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Our approach aims to restore viral immunity for patients fighting life-threatening infections through allogeneic, off-the-shelf, virus-specific T cell (VST) therapies.
The Global Leader
Our revolutionary, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies are designed to treat immunocompromised patients.
We are committed to preventing and defeating life-threatening viral diseases with revolutionary, allogeneic cell therapies. With more than 20 years of clinical experience in virus-specific T cell therapies (VSTs), our team is progressing products from early-stage discovery to clinical trials, regulatory approval and commercialization.
Baylor College of Medicine
Our technology platform was developed by world-class scientists at the Baylor College of Medicine’s Center for Cell and Gene Therapy. We continue to collaborate on basic and translational research of novel cell therapies through sponsored research agreements. This collaboration with the Center for Cell and Gene Therapy has enabled us to translate our research into clinical protocols at Texas Children’s Hospital and Houston Methodist Hospital in pediatric and adult patients, respectively.
An affiliate of ElevateBio, AlloVir has access to the clinical, manufacturing, and commercial expertise of ElevateBio BaseCamp, a centralized cell and gene therapy manufacturing facility and innovation hub.